Repeated administration of STING agonists may suppress cancer-induced bone pain by reducing tumor burden, reducing bone destruction, by a neuronal mechanism involving direct suppression of nociceptor activity, or a combination of all three of these mechanisms. Here, STING1 is linked to neoplasm.